U.s. fda partial clinical hold lifted on ind for erydel's lead phase 3 asset erydex for the treatment of ataxia-telangiectasia

South san francisco, calif.--(business wire)---- $qncx--quince therapeutics, inc. (nasdaq: qncx), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced that the u.s. food and drug administration (fda or the “agency”) has lifted the partial clinical hold on erydel s.p.a's investigational new drug (ind) application for its lead phase 3 asset, erydex. pending the closing of quince's acquisition of erydel, quince.
QNCX Ratings Summary
QNCX Quant Ranking